Search
Citations & References (10)
Gibco™
PSC Cardiomyocyte Differentiation Kit
The Gibco™ PSC Cardiomyocyte Differentiation Kit consists of a set of serum-free and xeno-free media that enable efficient differentiation ofRead more
| Catalog Number | Quantity |
|---|---|
| A2921201 | 1 kit |
Catalog number A2921201
Price (EUR)
644,00
Each
Quantity:
1 kit
Price (EUR)
644,00
Each
The Gibco™ PSC Cardiomyocyte Differentiation Kit consists of a set of serum-free and xeno-free media that enable efficient differentiation of human pluripotent stem cells (PSCs) to contracting cardiomyocytes in as few as 8 days. Unlike other methods that require multiple components and longer assay duration, the PSC Cardiomyocyte Differentiation Kit can generate cardiomyocytes from pluripotent stem cells in a ready-to-use media format and in less time.
Comprised of three 1X media that require no thawing or mixing, each medium is used consecutively over a total of 14 days, resulting in functional cardiomyocytes that express relevant physiological markers, contract in culture, and can be subsequently maintained in culture for >15 days (maintenance medium also sold separately (Cat. No. A2920801)).
No thawing or mixing required
The PSC Cardiomyocyte Differentiation Kit is comprised of 1X media that do not require frozen storage, so no thawing or mixing of reagents. Simply warm the media and add to PSC culture.
Rapid production of cardiomyocytes
The PSC Cardiomyocyte Differentiation Kit is capable of producing contracting cardiomyocytes in as few as 8 days. Differentiated cardiomyocytes can be subsequently maintained in culture for >15 days.
Generation of high quality cardiomyocytes
Cardiomyocytes generated using the PSC Cardiomyocyte Differentiation Kit are functionally relevant, expressing key markers such as TNNT2, Nkx2.5, MYH6, and α-actinin; and contract in culture.
Comprised of three 1X media that require no thawing or mixing, each medium is used consecutively over a total of 14 days, resulting in functional cardiomyocytes that express relevant physiological markers, contract in culture, and can be subsequently maintained in culture for >15 days (maintenance medium also sold separately (Cat. No. A2920801)).
No thawing or mixing required
The PSC Cardiomyocyte Differentiation Kit is comprised of 1X media that do not require frozen storage, so no thawing or mixing of reagents. Simply warm the media and add to PSC culture.
Rapid production of cardiomyocytes
The PSC Cardiomyocyte Differentiation Kit is capable of producing contracting cardiomyocytes in as few as 8 days. Differentiated cardiomyocytes can be subsequently maintained in culture for >15 days.
Generation of high quality cardiomyocytes
Cardiomyocytes generated using the PSC Cardiomyocyte Differentiation Kit are functionally relevant, expressing key markers such as TNNT2, Nkx2.5, MYH6, and α-actinin; and contract in culture.
For Research Use Only. Not for use in diagnostic procedures.
Specifications
Cell TypeCardiomyocytes
Quantity1 kit
Shipping ConditionRoom Temperature
Product TypePSC Cardiomyocyte Differentiation Kit
Unit SizeEach
Contents & Storage
• 500 mL Cardiomyocyte Maintenance Medium
• 100 mL Cardiomyocyte Differentiation Medium A
• 100 mL Cardiomyocyte Differentiation Medium B
Store at 2–8° and protect from light.
• 100 mL Cardiomyocyte Differentiation Medium A
• 100 mL Cardiomyocyte Differentiation Medium B
Store at 2–8° and protect from light.
Frequently asked questions (FAQs)
Is StemFlex Medium compatible with downstream differentiation kits available from Thermo Fisher Scientific?
I used the Gibco PSC Cardiomyocyte Differentiation Kit and am not seeing good differentiation with my iPSC line. What should I do?
I am planning to use the PSC Cardiomyocyte Differentiation Kit. Which markers can I expected my differentiated cells to express?
How long can I maintain differentiated cells in culture using the Gibco PSC Cardiomyocyte Differentiation Kit?
Which population of cardiomyocytes is produced using the PSC Cardiomyocyte Differentiation Kit?
Citations & References (10)
Citations & References
Abstract
Cardiac disease modeling using induced pluripotent stem cell-derived human cardiomyocytes.
Journal:
PubMed ID:25815118
Causative mutations and variants associated with cardiac diseases have been found in genes encoding cardiac ion channels, accessory proteins, cytoskeletal components, junctional proteins, and signaling molecules. In most cases the functional evaluation of the genetic alteration has been carried out by expressing the mutated proteins in in-vitro heterologous systems. While
Generation of the human induced pluripotent stem cell (hiPSC) line PSMi004-A from a carrier of the KCNQ1-R594Q mutation.
Journal:Stem Cell Res
PubMed ID:30974404
'We generated human induced pluripotent stem cells (hiPSCs) from dermal fibroblasts of a male carrier of the heterozygous mutation c.1781?G?>?A p.R594Q on the KCNQ1 gene. hiPSCs, generated using four retroviruses each encoding for OCT4, SOX2, KLF4 and cMYC, display pluripotent stem cell characteristics, and can be differentiated into spontaneously beating
Reprogramming of Urine-Derived Renal Epithelial Cells into iPSCs Using srRNA and Consecutive Differentiation into Beating Cardiomyocytes.
Journal:Mol Ther Nucleic Acids
PubMed ID:31476669
'The generation of induced pluripotent stem cells (iPSCs) from patient''s somatic cells and the subsequent differentiation into desired cell types opens up numerous possibilities in regenerative medicine and tissue engineering. Adult cardiomyocytes have limited self-renewal capacity; thus, the efficient, safe, and clinically applicable generation of autologous cardiomyocytes is of great
Generation of human iPS cell line CBTCi001-A from dermal fibroblasts obtained from a healthy donor.
Journal:Stem Cell Res
PubMed ID:31706097
Human-induced pluripotent stem cell (hiPSC) CBTCi001-A line was generated from a healthy 30-year old male dermal fibroblasts using non-integrative reprogramming method using episomal-based plasmids expressing OCT4, SOX2, KLF4, and MYCL. Characterization of CBTCi001-A was confirmed by the expression of typical markers of pluripotency and differentiation potential in vitro.
Generation of the human induced pluripotent stem cell (hiPSC) line PSMi007-A from a Long QT Syndrome type 1 patient carrier of two common variants in the NOS1AP gene.
Journal:Stem Cell Res
PubMed ID:30878014
We generated human induced pluripotent stem cells (hiPSCs) from a symptomatic Long QT Syndrome (LQTS) type 1 patient, belonging to a South African (SA) founder population segregating the heterozygous mutation c.1022C?>?T p.A341V on the KCNQ1 gene. The patient is also homozygous for the two minor variants rs4657139 and rs16847548 on